登录 | 注册    关注公众号  
微信公众号
搜索
 >  Kits>PD-1 >EPH-V1

ELISA Assay Kit for Anti-PD-1 h-mAb in Human Serum

For research use only.

背景(Background)

How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®. Many investigational anti-PD-1 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.

重构方法(Reconstitution)

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

存储(Storage)

Upon receipt, please store all items at -20°C.

After reconstitution, the stock solution should be kept at -80°C.

原理(Assay Principles)

The enclosed ELISA assay kit for anti-PD-1 h-mAb in human serum is based on an enzyme immunoassay (ELISA) between recombinant PD-1 protein (ECD) and a biotinylated anti-PD-1 monoclonal antibody. The method employs the principle of competitive ELISA, allowing quantification of monoclonal anti-PD-1 antibodies in human serum.

The assay only involves the following steps:

1. Coat the plate with human PD-1;

2. Add the mixture of your sample and biotinylated anti-PD-1 antibody;

3. Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate;

4. Record the OD readings and analyze the serum concentration.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
PD-1靶点信息
英文全称:Programmed cell death protein 1
中文全称:细胞程序性死亡-1
种类:Homo sapiens
上市药物数量:16详情
临床药物数量:150详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定